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INTRODUCTION 
“For all the happiness that mankind can gain 
It is not in pleasure but in relief from pain” 
- John dyrden. 
 Pain is a fundamental biological phenomenon. The International 
Association for the Study of pain has defined pain as an unpleasant 
sensory and emotional experience associated with actual or potential 
tissue damage. Pain is always underestimated and under treated. The 
relief of pain during peri operative period is the main part of 
anaesthesia. 
 In 1784, James Moore used mechanistic concepts to promote 
neural compression as a useful method for providing surgical anesthesia. 
 In 1855, pain can be treated by circum-neural injection of pain 
relieving drug. At the same year, Gadecke of Germany isolated an 
alkaloid from leaves of coca plant. In 1860, Albert Nieemann was 
successful in isolating and naming the alkaloid from the leaves of 
erythroxylon coca. 
 In 1884, idea of injecting cocaine into nerve trunk introduced by 
William Halsted and Alfred Hall. After that Heinrich F Braun found that 
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adding epinephrine to cocaine prolonged the effect of local anaesthetics. 
But later, in 1911 G.Hirschel performed first percutaneous axillary 
brachial plexus block. 
 In 1911, Kullenkampff  introduced the classic supraclavicular 
approach of brachial plexus block. Winnie and Collins introduced the 
subclavian perivascular approach of brachial plexus block. 
 Moorthy introduced the modified lateral perivascular approach. 
With introduction of barbiturate and cyclopropane, the enthusiasm for 
block anaesthesia waned in early 1940s. In recent years however, the 
technique has had resurgence, due in large part to increased 
understanding of neural plasticity and the possibility of minimizing 
hospital stay length by effective use of regional block anaesthesia. 
 Several techniques have been used to prolong the duration of 
regional anesthesia. 
 Regional blocks remain a well accepted component of 
comprehensive anesthetic care. Its role has expanded from the operating 
suite into the arena of postoperative and chronic pain management. With 
appropriate selection and sedation, these techniques can be used in all 
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age groups. Skillful application of these blocks broadens the 
anesthesiologist's range of options in providing optimal anesthetic care.  
 Brachial plexus block is a commonly used technique for 
anesthesia of upper limb surgery due to its easy accessibility and 
simplicity with predictable landmarks. Bupivacaine is the most 
commonly administered drug in brachial plexus blocks, however, onset 
of action and duration of anesthesia are the limiting factors. To 
minimize these drawbacks, many drugs including Buprenorphine, 
Morphine, Verapamil, Sufentanil, Dexamethasone and Clonidine, have 
been co-administered with local anesthetic inorder to improve the 
quality of  block and duration of action. 
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ANATOMY OF THE BRACHIAL PLEXUS 
THE BRACHIAL PLEXUS:
 
Knowledge of the formation of the brachial plexus and of  its 
distribution is essential to the intelligent and effective use of the brachial 
plexus block for the surgeries in the upper limb. Close familiarity with 
the vascular, muscular and fascial relationships of the plexus throughout 
the formation and distribution is equally essential for the mastery of 
various techniques of Brachial plexus Blockade. 
 The brachial plexus is a network of nerve fibers, running from 
the spine, formed by the ventral rami of the lower four cervical and first 
thoracic nerve roots (C5-C8, T1).  
Function 
 The brachial plexus is responsible for cutaneous and muscular 
innervation of the entire upper limb. There are two exceptions to this: 
the trapezius muscle innervated by the spinal accessory nerve (CN XI) 
and an area of skin near the axilla innervated by the intercostobrachial 
nerve. 
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Fig.1 : Anatomy of Brachial plexus 
 
Fig.2  
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Course 
 After leaving their  Intervertebral foramina, the roots course 
anterolaterally and inferiorly to lie between the anterior and middle 
scalene muscles, which arise from anterior and posterior tubercles of 
cervical vertebrae respectively. Here they unite and form the trunks. 
 superior or upper -  C5-C6 
 middle                  - C7 
 inferior or lower  -  C8, T1 
 The prevertebral fascia invests both the anterior and middle 
scalene muscles, fusing laterally to enclose the brachial plexus in a 
fascial sheath. Trunks emerge from the lower border of the muscle 
running inferiorly and anterolaterally covering towards the upper border 
of the 1st rib, where they lie cephaloposterior to the subclavian artery. 
 At the lateral edge of the 1
st
 rib each trunk divides into anterior 
and posterior divisions passing inferior to the mid portion of clavicle. 
They reunite within the axilla to form the lateral, medial and posterior 
cords and related to the second part of the axillary artery. 
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 The anterior divisions from upper and middle trunk unite to 
form the lateral cord. The posterior divisions from all three trunks unite 
to form the posterior cord. The anterior divisions from the lower trunk  
continues as the medial cord. 
 At the lateral border of the pectoralis minor, the three cords 
divide into the peripheral nerves of the upper extremity. 
Lateral Cord 
i. Lateral pectoral nerve C5 –C7 
ii. Lateral head of median nerve C5-C7 
iii. Musculocutaneous nerve C5-C7 
Medial Cord 
i. Medial Pectoral nerve C8 - T1 
ii. Medial head of median nerve C8 - T1 
iii. Medial Cutaneous nerve of arm C8 - T1 
iv. Medial Cutaneous nerve of forearm C8 - T1 
v. Ulnar nerve C7, C8 - T1 
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Posterior Cord 
i. Upper Subscapular nerve C5-C6 
ii. Lower Subscapular nerve C5-C6 
iii. Nerve to latissimus dorsi C6, C7, C8 
iv. Axillary nerve C5-C6 
Posterior cord after giving its branches continues as Radial 
nerve ( C5, C6, C7, C8, T1). 
Branches from Roots 
a) Nerve to the serratus anterior C5, C6 and C7 
b) Muscular branches to 
- Longus cervices C5 - C8 
- Three Scalene C5 - C8 
- Rhomboids C5 
c) Twig to the Phrenic nerve C5  
Branches from Trunk 
a) Suprascapular nerve C5-C6 
b) Nerve to subclavius C5-C6  
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Relations 
 Brachial plexus has its roots between the scalene muscles, 
trunks in the posterior triangle of the neck, divisions behind the clavicle 
and cords at the level of the Axilla and nerves beyond the axilla. In the 
course it lies superior and posterior to the subclavian artery. Dome of 
pleura is anteromedial to the lower trunk and posteromedial to the 
subclavian artery .The trunks emerge between the fascia covering the 
anterior and middle scalene muscles. 
TECHNIQUE OF BLOCKADE 
Supraclavicular Approach to Brachial Plexus Blockade 
Classic Approach 
 Anatomical landmarks: The three trunks are clustered vertically 
over the first rib cephaloposterior to the subclavian artery. 
Neurovascular bundle lies inferior to the clavicle at about its midpoint. 
Position of the Patient 
 Patient is placed in a supine position and the head turned to 
opposite side from the side to be blocked. The arm is pushed down to 
depress the clavicle. 
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Fig.3 : Supraclavicular Brachial Plexus Block  
 
Fig.4 :  
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Technique 
 The midpoint of clavicle is identified and marked. The posterior 
border of sternocleidomastoid is felt, by asking the patient to raise the 
head while keeping the head turned to opposite side. The interscalene 
groove is palpated by rolling the fingers back from the posterior border 
of the lower end of the strenocleidomastoid muscle over the anterior 
scalene muscle. 
 The anterior and middle scalene muscles may be highligted by 
asking the patient to inspire vigorously. A mark is made in the groove 
1.5 to 2 cm above the midpoint of  the clavicle, palpation of subclavian 
artery confirms this landmark. On the right side, interscalene groove is 
palpated with the left index finger and the needle is inserted with the 
right hand and reversing the hands for the left side. 
 Under sterile aseptic precautions, an intradermal wheal is raised 
with 1ml of 2% xylocaine and a short bevelled 22gauge 3.5 -4 cm long 
needle is inserted at the marked point. Subclavian artery is guarded with 
thumb, the needle is directed caudally, posteriorly and slightly medially 
until paresthesia is elicited or first rib is encountered. 
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 Needle enters the fascial sheath 1-2cm deep to the skin 
approximately. Marked resistance will give way to pop as the fascia is 
pierced and paresthesia may occur. 
 The needle is held firmly and then the local anesthetic solution 
is injected after careful aspiration to exclude intravascular placement. If 
needle is in the subclavian artery the needle is taken out and directed 
posterolaterally to elicit paresthesia. 
 If the first rib is encountered without elicitation of paresthesia, 
the needle is systematically walked over the rib until the plexus or 
subclavian artery is located. The rib is contacted at a depth of 3-4 cm. 
The solution should flow without resistance. High resistance or pain on 
injection may indicate intraneural injection and the needle must be 
repositioned. Volume of local anesthetic that can be used is 25-40 ml 
depending on the weight of the patients. When large volumes are used 
the sheath may be felt to distend during injection and is easily 
distinguished from the subcutaneous swelling of an extra fascial 
injection. To encourage the spread proximally, digital pressure distal to 
the needle point may be used and digital pressure proximal to needle 
insertion point may help to encourage distal spread. 
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Complications 
1.  Supraclavicular approach has the highest risk of pneumothorax 
0.5-6% when compared to other techniques. 
2.  Unilateral Phrenic nerve block can occur but has no significance 
3.  Horner syndrome – occurs when large volume is used, resolves 
spontaneously 
4.  Unintentional intravascular injection 
5.  Stellate ganglion block and recurrent laryngeal nerve palsies 
(very rare) 
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PHARMACOLOGY OF LIGNOCAINE 
 
 
Lignocaine was synthesized in 1943 in Swedan by Lofgren and 
was introduced into clinical practice in 1948. 
DESCRIPTION 
Lignocaine hydrochloride is 2-diethylamino-aceto-2'6xylilide 
hydrochloride monohydrate. It appears as a white, odourless crystalline 
powder. It is very soluble in water, freely soluble in chloroform and in 
ethanol .It is practically insoluble in ether. 
Molecular formula  - C14H22 N20 Hcl.H20  
 Molecular weight   - 288.8  
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Lignocaine hydrochloride injection is an isotonic, sterile solution 
containing Lignocaine hydrochloride B.P., 1% or 2%, and sodium 
chloride, B.P., in water for injection. Lignocaine is a weak base with 
amphiphillic property. A hydrophilic amine on one side and a 
lipophillicaromatic residue on the other side and are joined through an 
amide linkage. 
MECHANISM OF ACTION: 
Local anesthetics block the nerve conduction by decreasing the 
entry of sodium ions during upstroke of action potential. As the 
concentration of local anaesthetic is increased the rate of rise of action 
potential and maximum depolarization decreases causing slowing of 
conduction. Finally local depolarization fails to reach the threshold 
potential and conduction block ensues. The local anesthetics interact 
with a receptor situated within the voltage sensitive sodium channel and 
raise the threshold of channel opening. 
Sodium channel has an activation gate (A) near its extracellular 
mouth and an inactivation gate (I) at the intracellular mouth. In the 
resting state, the activation gate is closed. Threshold depolarization of 
the membrane opens the activation gate allowing sodium ions to flow in 
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along the concentration gradient. Within a few milliseconds inactivation 
gate closes and ion flow ceases. 
The local anesthetic receptor is located within the channel in its 
intracellular half. Local anesthetic traverses the membrane in its 
lipophillic form (B+), reionises in the axoplasm and approaches the LA 
receptor through the intracellular mouth of the channel. It is the cationic 
form of local anesthetic (BH+), which primarily binds to the LA 
receptor. The receptor has higher affinity or is more accessible to local 
anesthetic in the activated state compared to the resting state. Binding of 
LA to its receptor stabilizes the channel in the inactive state and thus 
reduces the probability of channel opening. 
Action of receptors within the sodium channel accounts for 90% 
of nerve blocking effect. Nonspecific membrane expansion accounts for 
the remaining 10% of the action and is analogous to the electrical 
stabilization produced by a number of non-polar, purely lipid solvable 
substances such as barbiturates, general anesthetics and Benzocaine. 
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PHARMACOLOGICAL ACTION: 
1. LOCAL - Minimal local irritant action and blocks 
sensory nerve endings, nerve trunks, neuro-
muscular junction, and ganglionic receptors. 
2. REGIONAL - Autonomic fibers are generally more 
susceptible than somatic fibers. Among the 
somatic afferents, the order of blockade is 
pain, temperature, touch, deep pressure. 
3. SYSTEMIC - Effect is mainly on CVS or CNS. 
CVS: In cardiac tissue, a therapeutic serum concentration (1.5 to 
6. micrograms / ml) of Lignocaine will produce the following effects: 
a. Depression of slow spontaneous depolarization (phase 4), 
that is the automaticity of isolated, non-polarised purkinje fibres, while 
having little effect on membrane responsiveness, conduction velocity, or 
cardiac output. Automaticity due to stretch, hypoxia or catecholamine’s 
can also be suppressed by Lignocaine. 
b. Shortening of action potential period and effective 
refractory period of purkinje and ventricular cells. 
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Thus it has a stabilizing effect on cell membrane of cardiac tissue. 
It also stabilizes aberrant conduction. 
CNS: Low plasma concentration of LA is likely to produce 
numbness of tongue and circumoral tissues. As plasma concentration 
increases it crosses blood-brain-barrier and produces restlessness, 
vertigo, tinnitus and difficulty in focusing. Then slurred speech and 
skeletal muscle twitching occur. Lignocaine causes drowsiness before 
seizures. Seizures are classically followed by CNS depression, which 
may be accompanied by hypotension and apnea. 
PHARMACOKINETICS 
Following IV injection, the blood level of Lignocaine declines 
due to rapid distribution into various tissues including the heart , with a 
half-life of 7 to 10mins, within the first hour. After this initial phase, the 
half-life is 90 to 120mins (metabolism and excretion). Absorption is 
slow in regional anesthesia. 
METABOLISM AND EXCRETION 
The principle metabolic pathway of Lignocaine is oxidative 
dealkylation in the liver to monoethylglycinexylidine following by 
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hydrolysis of this metabolite to xylidine. Monoethylglycinexylidine has 
approximately 80% of the activity of Lignocaine for protecting against 
cardiac dysrhythmias. This metabolite has a prolonged elimination half 
time. Xylidine has approximately 10% of the activity of Lignocaine.  
Hepatic disease or decrease in hepatic flow, which may occur 
during general anesthesia, decreases the rate of metabolism of 
Lignocaine. Excretion is through the kidneys. Approximately 90% of 
the dose is excreted as metabolites and less than 10% is excreted 
unchanged in the urine. 
DOSAGE 
For regional anesthesia: 3mg/kg, with adrenaline 7mg/kg. For 
cardiac arrhythmias, therapeutic serum concentration of  Lignocaine is 5 
to 20micromol/L or 1.5 to 6.0 micrograms/ ml. In order to obtain 
therapeutic blood levels rapidly, a single intravenous dose of 1mg/kg 
should be given over 1 to 2 minutes. The initial effect will occur in 2 to 
4 minutes, and may last as long as 20 minutes. This should be followed 
within 10 minutes, by a continuous infusion at the rate of 2 to 4 
mgs/min. In order to maintain therapeutic blood levels, the initial dose 
may be repeated by two more injections at 15 to 20 min intervals but it 
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should not exceed 300mg of Lignocaine within a 1 hour period. Since it 
has a very narrow therapeutic window, infusion should be promptly 
stopped when there is an undue prolongation of PR interval or QRS 
complex .To attenuate the cardiovascular stress response to intubation, 
Lignocaine 1.5mg/kg IV 3 min prior to laryngoscope should be given. 
ADVERSE EFFECTS /TOXICITY: 
1. Due to high plasma levels as a result of excessive dosage, rapid 
absorption, delayed elimination or inadvertent IM injection during 
local anesthetic use. 
2. CNS: Lightheadedness, drowsiness, disorientation, confusion,  
nervousness, agitation, psychosis, euphoria, tinnitus, blurred 
vision, slurred speech, numbness, twitching, tremors, convulsions, 
unconsciousness, seizures, coma, respiratory depression and 
arrest.  
3. CVS: Hypotension, bradycardia, arrhythmias, heart block and 
CVS collapse which may lead to cardiac arrest. Meth-
hemoglobineamia may occur following IV administration. 
4. HYPERSENSITIVITY: Rare with Lignocaine. 
5. NEUROLOGICAL SYSTEM: Persistent anesthesia, paresthesia, 
weakness, paraplegia of lower extremities and loss of sphincter 
control may occur. 
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PHARMACOLOGY OF BUPIVACAINE
 
 Bupivacaine is an amide linked local anesthetic. It is a 
hydrochloride salt of 1-butyl-N-(2, 6-dimethylphenyl) piperidine-2- 
carboxamide and is presented as a racemic mixture. 
 It was synthesized by Ekenstam in 1957. 
 First report of its use was published in 1963 by Telivuo. 
 It is derived from Mepivacaine and is a very stable compound and 
may be autoclaved repeatedly.  
 
 Pka  -  8.1 
 Molecular weight  -  288 
 Protein binding  -  95% 
 Lipid solubility  -  28 
 Elimination half life -  210 minutes 
 Toxic plasma concentration  -  >1.5mg/ml 
 Approximate duration of action  -  175minutes 
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Availability 
 Ampoules - 0.5% Bupivacaine hydrochloride with dextrose 
(Heavy) 4cc- 0.5% Bupivacaine hydrochloride 
(plain)  
 Vials  -  0.25% and 0.5% Bupivacaine hydrochloride 
20cc  
 Dosage  - Maximum dosage 3mg/kg body weight. 
Uses 
 Spinal anesthesia 
 Epidural anesthesia 
 Caudal anesthesia 
 Continuous epidural anesthesia 
 Peripheral nerve block 
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Onset time and duration of action 
Site of action Onset (minutes) Duration (minutes) 
Intrathecal 5 90-120 
Epidural 15-20 165-225 
Brachial plexus 10-20 600 
 
Pharmacokinetics 
 Once injected Intrathecal, it gets absorbed by the nerve rootlets 
and results in the desired effect. It is rapidly absorbed from the site of 
injection, but the rate of absorption depends on the vascularity at the site 
and presence of vasoconstrictors. High lipid solubility of Bupivacaine 
makes it easy for nerve and vascular tissue penetration. 80-95% of the 
absorbed Bupivacaine binds to the plasma proteins. 
Distribution 
 Rapid distribution phase: (α) In this phase the drug is distributed 
to highly vascular region t½ of α - being 2.7 minutes. 
 Slow disappearance phase: (β) In this phase the drug is distributed 
to slowly equilibrating tissues t1/2 of β – being 28minutes. 
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 Biotransformation and excretion phase: (δ) T1/2 of δ is 3.5hours. 
Clearance is 0.47 liters/ minute. 
Biotransformation 
 Possible pathways of metabolism of Bupivacaine include 
aromatic hydroxylation and conjugation. Only the N-dealkylated 
metabolite, N-desbutyl Bupivacaine has been measured in blood (or) 
urine after epidural (or) spinal anesthesia. Alpha-1 acid glycoprotein is 
the most important plasma protein binding site of Bupivacaine and its 
concentration is increased by many clinical situations including post 
operative trauma. 
Excretion 
 It is through the kidney; 4-10% of the drug is excreted 
unchanged. 
MODE OF ACTION 
a)  Site of action 
i)  Peripheral nerve rootlet, fine nerve filaments 
ii)  The spinal nerve rootlet fine nerve filaments having a large 
surface area are exposed to the local anesthetics 
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iii) Posterior and lateral aspects of the spinal cord itself. 
b)  Sodium Channel blockade 
 They impede sodium ion access to the axon interior by 
occluding the transmembrane   sodium channels thus delaying the 
process of depolarization and axon remains polarized. It is a 
nondepolarization blockade. 
Pharmacodynamics 
 It has got a longer duration of action but a slower onset. 
Cardio Vascular System 
 It depresses myocardial automaticity (spontaneous phase IV 
depolarization) and reduces the duration of the refractory period. At 
high concentrations, myocardial contractility and conduction velocity 
are also depressed. It causes some degree of arteriolar vasodilatation. 
The ensuing combination of bradycardia, heart block, and hypotension 
may culminate in cardiac arrest. 
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Respiratory System 
 It relaxes bronchial smooth muscle. Apnea can results from 
phrenic and intercostal nerve paralysis or depression of the medullary 
respiratory center following direct exposure to drug. 
Toxicity 
  Toxicity is related to plasma level of unbound drug and more 
likely due to an inadvertent intravenous injection. Systemic toxicity 
reactions primarily involve central nervous system and cardio vascular 
system. The blood level required to produce central nervous system 
toxicity is less than that required to produce circulatory collapse. 
Central Nervous System Toxicity 
 Early symptoms are circumoral numbness, paresthesia of 
tongue, and dizziness. Sensory complaints include blurred vision and 
tinnitus. Excitatory signs (eg, nervousness, restlessness, agitation, 
paranoia) often precede central nervous system depression (eg, slurred 
speech, drowsiness, unconsciousness). 
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 Muscle twitching is a premonitory sign of the onset of tonic 
clonic seizures. Respiratory arrest often follows. The excitatory 
reactions are a result of selective blockade of inhibitory pathways. 
Cardiac Toxicity 
 The rate of depolarization in fast conducting tissue of purkinje 
fibres and ventricular muscle is decreased. The rate of recovery of 
Bupivacaine induced block is slower than that of Lignocaine. 
 Extremely high concentration of the drug causes sinus 
bradycardia, hypotension, idioventricular rhythms, atrioventricular heart 
block, and life threatening arrhythmias such as ventricular tachycardia, 
ventricular fibrillation and cardiac arrest. 
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CLONIDINE HYDROCHLORIDE 
Introduction 
 Clonidine hydrochloride is a centrally acting selective partial 
alpha -2 agonist introduced in early 1960s, it was during its use as a 
nasal decongestant that its anti- hypertensive property was found out. 
Subsequently more insights into the pharmacological properties have led 
to its use in clinical anesthesia practice as well. 
 Clonidine hydrochloride is an imidazoline compound. It exists 
as a mesomeric compound. The chemical name is 2-(2, 6- 
dichlorophenylamino)-2-imidazoline hydrochloride. The structural 
formula is C9H9C12N3HCl. 
 The molecular weight is 266.56. Clonidine is an odorless, bitter, 
white, crystalline substance, soluble in alcohol and water. 
 Clonidine improves the quality of anesthesia, provides a more 
stable cardiovascular course during anesthesia, presumably because of 
their sympatholytic effect and need for lower dose of cardio active 
anesthetic and reduces the dose requirement of the anesthetic agent. 
Clonidine may reduce the halothane MAC by up to 50% in a dose 
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dependent manner. Clonidine potentiates the anesthetic action of the 
local anesthetics with fewer side effects in peripheral nerve blocks and 
central neuraxial blockade. 
Availability 
 Available as one ml ampoule containing 150 micrograms . It 
should be stored below 25 degree Celsius. 
Location of Alpha 2 Receptors 
 Primary afferent terminals,  on neurons in the superficial 
laminae of spinal cord and brainstem nuclei. 
Mechanism of Action 
 Clonidine is a centrally acting selective partial α2 adrenergic 
agonist with a selectivity ratio of 220: 1 in favor of α2 receptors. 
 The three subtypes of α2 receptors are α2a, α2b, α2c. α2a 
receptors mediate sedation, analgesia, sympatholysis. α2b receptors 
mediate vasoconstriction and anti- shivering. The startle response may 
reflect the activation of α2c receptors. The drug is lipid soluble, 
penetrates the blood brain barrier to reach the hypothalamus and 
medulla when injected epidurally. It stimulates the inhibitory α2 
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adrenoreceptors to reduce the central neural transmission in the spinal 
neurons. 
 Inhibition of substance- P release is believed to be involved in 
the analgesic effect. 
 The α2 adrenoreceptors are located on the afferent terminals of 
both peripheral and spinal neurons in the superficial laminae of the 
spinal cord and within several brain stem nuclei implicated in analgesia. 
The superficial laminae contain three groups of neurons: tonic, adapting, 
single- spike firing, all of which receive their primary sensory input 
from Aδ and C fibres. Clonidine inhibits voltage gated Na+ and K+ 
channels and suppresses the generation of action potentials in tonic- 
firing spinal dorsal horn neurons, contributing to analgesic effect. The 
ability of Clonidine to modify the function of potassium channels in the 
CNS (cell membrane become hyperpolarized) may be mechanism for 
profound decrease in anesthetic requirements. 
 Another contribution to analgesic effect may be through the 
release of acetylcholine in the neuraxial region. The α2 adrenergic 
agonists also enhance analgesia of intraspinal opioids. Sedation is 
produced by its action on locus ceruleus. 
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 Clonidine’s effect on the blood pressure is a complex one after 
neuraxial or systemic administration because of opposing action at 
multiple sites. In the nucleus tractus solitarius and locus ceruleus of the 
brain stem, activation of post- synaptic α2 adrenoreceptors reduces 
sympathetic drive. It also activates nor-adrenergic imidazoline 
preferring binding sites in the lateral reticular nucleus producing 
hypotension and anti- arrythmogenic action. In the periphery it acts on 
pre-synaptic α2 adrenoreceptors at sympathetic terminals reduces the 
release of nor-epinephrine causing vasorelaxation and reduced 
chronotropic drive. The brainstem and the peripheral effects of α2 
adrenoreceptor stimulation are counterbalanced by the direct peripheral 
vasoconstriction through its action on α2 adrenoreceptors from the 
circulating concentrations of Clonidine. 
 Sedation is a desired property. Clonidine produces a dose 
dependent sedation at the dose of 50micrograms or more in less than 20 
minutes regardless of the route of administration. 
 Clonidine doesn’t induce profound respiratory depression even 
after massive overdose and they do not potentiate respiratory depression 
from opioids. 
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 In peripheral nerves it produces a minor degree of blockade at 
high concentrations with some preference for C- fibres in the peripheral 
nerves and this effect in part enhance the peripheral nerve block when 
added to local anesthetics, probably because the α2adrenoreceptors are 
lacking on the axons of peripheral nerves. 
Pharmacokinetics 
 Clonidine is well absorbed orally and is nearly 100% bio 
available and reaches peak plasma concentration within 60 to 90 
minutes. The mean half life of the drug in plasma is about 9 to 12 hours, 
with approximately 50% metabolized in the liver whereas is it is 
excreted in unchanged from the kidney, and its half- life can 
dramatically increase in the presence of impaired renal function. 
 A transdermal delivery system is available in which the drug is 
released at a constant rate for about a week. Three or four days are 
required to achieve steady state concentration. 
 Clonidine is highly lipid soluble .It readily distributes into 
extra- vascular sites including the central nervous system. 
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300 micrograms intravenously over 10min Produces: 
 Distribution t ½  : 11 ± 9 minutes. 
 Elimination t½ : 9 ± 2 hour, 41 hours in severe renal 
dysfunction. 
Volume of distribution :  2.1 ± 0.4 l/kg 
Plasma protein binding  :  20-40 % in vitro. 
Metabolism  :    major Metabolite, p- hydroxyClonidine. 
Excretion 
 70% of the dose, mainly in the form of unchanged parent drug 
(40-60%) in urine. So, the elimination t1/2 of Clonidine varies as a 
function of creatinine clearance. In subjects undergoing hemodialysis 
only 5% of the body Clonidine store was removed. 
Dosage Regimen 
Oral   -  3-5 μg/kg 
Intramuscular  -  2 μg/kg 
Intravenous  -  1-3 μg/kg 
Spinal   -  50-100 μg 
Epidural  - 1-2 μg/kg 
Transdermal  -  0.1- 0.3 mg released per day 
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Precautions 
1. In patients with renal insufficiency, lower dose is needed. 
2.  Sudden withdrawal of prolonged continuous epidural infusion 
produces hypertensive crisis. So it should be gradually 
discontinued over 2 to 4 days. 
3.  Use with caution in patients with cerebrovascular or coronary 
insufficiency. 
4.  If a patient with beta blocker is on continuous epidural therapy, 
beta blocker should be withdrawn several days before 
discontinuation of epidural Clonidine. 
5.  Intrathecal / epidural Clonidine often causes bradycardia that if 
symptomatic can be treated with inj. Atropine. 
Contraindications 
1.  Known hypersensitivity to Clonidine or components of the 
product. 
2.  In patients with bradyarrhythmia or AV block. 
3.  Patients with severe cardiovascular disease 
4.  Patients with cardiovascular / hemodynamic instability. 
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Interactions 
1.  Clonidine may potentiate the CNS- depressive effect of 
barbiturates, alcohol, or other sedative drugs.  
2.  Narcotics may potentiate the hypotensive effects of Clonidine. 
3.  Tricyclic antidepressants may antagonize the hypotensive 
effects of Clonidine. 
4.  Concomitant administration of drugs with a negative 
chronotropic/ dromotropic effect (beta blockers, digoxin) can 
cause or potentiate bradycardia rhythm disturbances. 
5.  Beta blockers may potentiate the hypertensive response seen 
with Clonidine withdrawal. 
6.  Epidural Clonidine may prolong the duration of pharmacologic 
effects of epidural local anesthetics, neostigmine, opioids  and 
other drugs. 
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Uses 
1. Preanaesthetic Medication 
 Oral Clonidine Preanaesthetic medication (5 μg/kg ) (a) blunts 
reflex tachycardia associated with direct laryngoscopy for intubation of 
trachea, (b) decrease intraoperative lability of blood pressure and heart 
rate, (c) decrease plasma catecholamine concentrations, and (d) 
dramatically decrease anesthetic requirements for inhaled and injected 
drugs. Clonidine also attenuates the rise in intraocular pressure 
associates with laryngoscopy and intubation. 
2.   Epidural block 
Clonidine as a sole agent or in combination with opioids or local 
anaesthetics provide excellent analgesia in labour analgesia. Epidural 
Clonidine is also indicated for the treatment intractable pain, which is 
unresponsive to maximum dose of oral or epidural opioid, as do patients 
with reflex sympathetic dystrophy, neuropathic pain. 
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3.   Spinal anesthesia 
  Clonidine combined with local anesthetics improves the quality 
and duration of the block, minimize the tourniquet pain during lower 
limb surgery, and prevents shivering. 
4.   Caudal anesthesia 
  Clonidine combined with local anesthetics increases the 
duration of anesthesia and analgesia by 2 or 3 times without 
hemodynamic side effects. Dose 2-3μg/kg 
5.   Peripheral nerve block  
  Clonidine prolongs the duration of anesthesia and analgesia 
with local anesthetics by two times in a dose of 75 to150 micro grams. 
6.     Bier’s block 
  50 microgram of Clonidine enhances the tolerance of tourniquet 
7.   It is also used in intra articular analgesia. 
8.   Protection against perioperative myocardial ischemia; Clonidine 
decreases myocardial ischemia, infarction and mortality 
following cardiovascular surgery. 
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9.  To treat hypertensive crises 
10.  Diagnosis of pheochromocytoma; Clonidine, 0.3 mg will 
decrease the plasma concentrations of catecholamine in normal 
patients but not in the presence of pheochromocytoma. 
11.  Treatment of shivering; Administration of Clonidine, 75 μg IV 
stops shivering by inhibit thermoregulatory control. 
12.  Treatment of opioid and alcohol withdrawal syndrome; 
SIDE EFFECTS 
1.  The most common side effects are sedation and xerostomia. 
2.  Cardiovascular complaints are bradycardia, hypotension, and 
ECG abnormalities like sinus node arrest, junctional 
bradycardia; high degree AV block and arrhythmia are reported 
rarely. Occasionally require treatment of bradycardia with I.V 
anticholinergics. Orthostatic hypotension occurs rarely. 
3.  Rebound hypertension; Abrupt discontinuation of Clonidine can 
result in rebound hypertension as soon as 8 hours and as late as 
36 hours after the last dose. Symptoms of nervousness, 
headache, diaphoresis, abdominal pain, and tachycardia often 
precede the actual increase in systemic blood pressure. 
Labetalol is useful in treatment of rebound hypertension. 
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4.  Skin rashes are occurs frequently. 
5.  Impotence occurs occasionally. 
Over Dosage and Treatment 
 There is no specific antidote for Clonidine over dosage. 
Supportive measures like Atropine, Ephedrine, and i.v fluids are 
enough. 
 Yohimbine partially reverses the analgesia and sedation but not 
the BP and heart rate changes produced by the epidural Clonidine 
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REVIEW OF LITERATURE 
1. Winnie and Ramamoorthy (1977)1 described that the trunk of 
brachial plexus are so arranged that the central long fibres supply 
the extremities of the limb and the short peripheral fibres supply 
more proximally. 
Winnie grouped the fibres into two :the peripheral Mantle bundle  
contains the outer motor and inner sensory  fibres  corresponding to all 
the early branches of the brachial plexus being motor and a central core 
bundle with the outer motor fibres which supply the muscles of the 
forearm and the inner sensory fibres carries sensation from hand. Thus 
the order of blockade is loss of motor power to the shoulder and upper 
arm, sensory loss to the upper arm, loss of motor power of the forearm 
and sensory loss of the hand. 
2. Lanz. E, Theiss (1979)2- compared the supraclavicular and the 
interscalene approach of brachial plexus block. They concluded 
that with the Supraclavicular block, motor and sensory blockade 
of all the nerves of the brachial plexus occurred with about the 
same frequency. Following both the techniques, blockade 
developed from the proximal to distal and the motor blockade 
preceding the sensory block. 
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3. Eledjam JJ, Deschodt J et al  (1991)3;they studied the effects of 
alpha adrenergic agonists(Clonidine and Epinephrine ) with 
Bupivacaine  in  brachial plexus block. In this study, group A (30 
patients) received 150 micrograms of Clonidine and 30 patients in 
group B received 200 micrograms of Adrenaline. In Clonidine 
group there is no difference in the onset of sensory blockade and 
motor blockade compared to Adrenaline. Duration of motor 
blockade prolonged in Clonidine group compared to Adrenaline 
group. The block produced with Clonidine group was longer and 
superior to that with Adrenaline. The injection of Clonidine into 
the brachial plexus sheath is a better alternative to Epinephrine to 
prolong the duration of analgesia following upper limb surgery.  
4. Dorothee M. Gaumann et al 4 (1992); Clonidine enhances the 
Effects of Lignocaine on C-Fiber Action Potential. This study 
concluded that the enhancing effect of a low dose of Clonidine 
(500μM) on Lignocaine induced (500μM) inhibition of C-fiber 
AP might explain  that Clonidine  prolongs the action of 
Lignocaine at approximately 1000-fold lower concentrations than 
Lignocaine, in peripheral nerve block  
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5. Hickey R et al (1992)5 did a comparative study on the 
effectiveness of 0.25% Ropivacaine and 0.25% Bupivacaine in 
subclavian perivascular brachial plexus block .They concluded 
that  0.25% Ropivacaine and 0.25% Bupivacaine required 
frequent supplementation and is not recommended concentrations 
to provide brachial plexus block.  
6. Brown DL (1993)6- did a study on brachial plexus anesthesia and 
analyzed the various sites at which the plexus can be blocked. 
They studied the supraclavicular, interscalene, infraclavicular and 
axillary approaches. They concluded that the supraclavicular 
block produces anesthesia of the entire upper extremity in the 
most efficient manner than the other brachial plexus block 
technique. 
7. Filos et al (1994) 7; Conducted a double blind placebo controlled   
study to evaluate   the efficacy of Intrathecal Clonidine on pain 
following LSCS under general anaesthesia. The results suggest 
that Intrathecal Clonidine 150 micrograms is effective in 
controlling pain following caesarean section but may cause side 
effects such a hypotension, sedation and dryness of mouth. 
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8. Gentili M et al(1996)8; they did comparative study in a group of 
40 patients to assess the potential analgesic effect of Clonidine 
after intra articular administration. They concluded that low dose 
of intra articular Clonidine produces analgesia and it is unrelated 
to vascular uptake of the drug. 
9. F J Singelyn et al (1996)9 studied the minimum dose of 
Clonidine required to prolong the duration of analgesia and 
anesthesia after an axillary brachial plexus block. They concluded 
that the minimum dose of Clonidine required was 0.5µg/kg to 
prolong the duration of anesthesia and analgesia after an axillary 
brachial plexus blockade and at this dose there was no side effects 
noted. 
10. El saied AH et al(2000)10; studied the effect of using Clonidine 
as an additive to Ropivacaine in axillary brachial plexus block. 
Clonidine group received 40ml  Ropivacaine 0.75% with 
Clonidine 150µg and the control group received local anesthetic 
with 1 ml of normal saline .They concluded that Clonidine group 
had prolonged duration of motor blockade,sensory blockade and 
analgesia without any significant side effects. 
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11. Franco CD et al (2000) 11did a study on subclavian perivascular 
block and its success using a nerve stimulator. They concluded 
that the subclavian perivascular technique is a consistently 
effective block for surgeries of the upper extremities. This is 
explained by the smallest size of the plexus and its smallest sheath 
volume at that site of injection 
12. Castia A.et al (2001)12conducted a study for improving 
postoperative analgesia after axillary brachial plexus anesthesia 
by using Clonidine as an adjuvant to Ropivacaine in axillary 
brachial plexus block. By adding 1μg/kg of Clonidine to 20 ml of 
Ropivacaine 0.75% for axillary brachial plexus anesthesia,  first 
analgesic request was delayed by 3hours postoperatively .There 
was no clinically relevant effects on the degree of sedation and 
cardiovascular homeostasis . 
13. Erlacher W et al 13(2001); evaluated the efficacy of adding 
Clonidine to Mepivacaine, Ropivacaine and Bupivacaine in 
axillary perivascular brachial plexus block by comparing 3 
groups. They concluded that the onset of sensory block with 
Mepivacaine is faster than Ropivacaine and Bupivacaine but the 
duration of motor blockade and sensory blockade was prolonged 
by Clonidine in the Mepivacaine and Bupivacaine groups 
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14. D. Hutschala et al14 (2004); Clonidine added to Bupivacaine 
enhances and prolongs analgesia after brachial plexus block by a 
local mechanism in healthy volunteers. This study suggested that 
admixture of Clonidine 2µg /kg to Bupivacaine 0.25% 40 ml plus 
Epinephrine prolongs and enhances brachial plexus blockade by 
270 minutes compared without Clonidine. Lower plasma 
concentrations of Clonidine after peripheral nerve blockade 
strongly suggest a local effect. 
15. Duma et al15(2005) ;conducted a randomized controlled study in 
axillary brachial plexus block using Clonidine as an adjuvant to 
local anesthetic. Four groups of 20 patients in each group were 
investigated using 40 ml of .05%  LevoBupivacaine plus i)1 ml of 
0.9% NaCl, ii)150µg Clonidine,40 ml of  LevoBupivacaine plus i) 
1 ml of 0.9% NaCl, ii)150µg Clonidine.the onset of motor an 
sensory blockade and duration of analgesia was noted .They 
concluded that there is no significant difference between groups, 
but a significantly higher variance was found in the Clonidine 
added groups .This finding is attributed to Clonidine.  
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16. Upadhyay P et al(2005)16; studied the effects of Clonidine added 
to Bupivacaine for caudal anesthesia in 50 pediatric patients 
.They concluded that the duration of analgesia was significantly 
increased when Clonidine 1µ/kg is added to 0.75ml/kg 
Bupivacaine(0.25%) in caudal blockade and without side effects.  
17. Adnan T et al(2005)17; conducted a study with Clonidine as an 
adjuvant to local anesthetic in axillary block on 28 adult chronic 
renal failure patients posted  for arteriovenous fistula .The control 
group received 40 ml of Lignocaine with 1 ml of saline and the 
Clonidine group received 40 ml of Lignocaine with 150µg of 
Clonidine. They concluded that Clonidine as adjuvant to 
Lignocaine in axillary blocks for arteriovenous fistula 
construction prolonged blockade, provides sedation and reduces 
heart rates and blood pressures. 
18. Shivinder singh et al(2010)18;studied the effects of Clonidine as 
adjuvant to Bupivacaine  and the effects of  Bupivacaine alone on 
supraclavicular brachial plexus block.Group A received 40ml 
Bupivacaine 0.25%  with 150µg of Clonidine, group B received 
40 ml of Bupivacaine 0.25% with 1 ml of normal saline. They 
concluded that, addition of Clonidine resulted in faster onset of 
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motor and sensory blockade, prolonged duration of analgesia 
without any hemodynamic changes, sedation or any other adverse 
effects. 
19. shobana gupta et al(2010)19; studied the analgesic effect of 
combination of epidural Clonidine of  1µg/kg and Bupivacaine 
with epidural Bupivacaine(1.5ml/kg) alone in postoperative pain 
relief of knee replacement surgery. They concluded that Clonidine 
group had prolonged duration of motor and sensory blockade and 
duration of analgesia without side effect. 
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AIM OF THE STUDY 
Aim of the study is to evaluate the following observations in 
patients receiving either Clonidine or the placebo as an adjuvant to local 
anesthetic mixture in supraclavicular brachial plexus block. 
1. Onset of motor blockade. 
2. Onset of sensory blockade. 
3. Duration of motor blockade. 
4. Duration of sensory blockade.  
5. Intraoperative Hemodynamic changes. 
6. Sedation score. 
7. Complications.  
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MATERIALS AND METHODS 
This study was a prospective randomized single blinded 
controlled study. After receiving the institutional ethical committee 
approval and informed consent from the patients they were randomly 
allocated into two groups.  
A total number of 60 adult patients of  both sexes in the age group 
of 20 to 60 years belonging to ASA I /II category who were posted for 
various type of  upper limb surgeries in the department of orthopaedics 
at Rajiv Gandhi Government Hospital formed the study group. 
Groups: 
Group A: 30 patients received 15 ml 2% Lignocaine with 
Adrenaline (1in 200000) + 15 ml 0.5% Bupivacaine with 2 ml of 0.9% 
normal saline.  
Group B: 30 patients received 15 ml 2% Lignocaine with 
Adrenaline (1in 200000) + 15 ml 0.5% Bupivacaine with 1µg /kg of 
Clonidine. 
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INCLUSION CRITERIA: 
 ASA physical status I / II 
 Age 20 to 60 years 
 Patients undergoing upper limb surgery who have given 
informed consent 
EXCLUSION CRITERIA: 
 ASA physical status III / IV 
 Patients with coagulation abnormalities 
 History of allergy to local anesthetics 
 Patients with progressive neurological disorders, severe 
liver or kidney disease 
 Patients having opposite side pneumothorax or 
collapsed lung 
 Patients having bilateral upper limb surgery 
 Patchy or inadequate analgesia 
 Patient refusal 
 Patient requiring conversion to GA 
 Patient not fitting into inclusion criteria 
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EQUIPMENTS: 
 Sterile tray 
 Sterile towel 
 Sterile swabs 
 Sponge holding forceps 
 Povidone iodine solution 
 10 ml syringe 
 2ml syringe with 24 G needle 
 0.5% Bupivacaine vial 
 Freshly prepared 2% Lignocaine with Adrenaline 1:200000 
vial 
 Clonidine ampoule  
 25 G spinal needle 
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METHODOLOGY: 
Subclavian perivascular technique: 
1. IV line was started for all the patients with 18 G I.V cannula after 
connecting monitors to the patient and injection Glycopyrollate 
0.2mg was given intravenously 15mins before the surgery. 
2. Patient was positioned on the table and proper illumination was 
done at the site of block. 
3. For continuous neurological evaluation no sedative drugs were 
administered preoperatively .Preoperative counseling was given 
to patients regarding the procedure and surgery to allay anxiety. 
4. Patient was placed in supine position with head turned to the side 
opposite to the side that is to be injected. 
5. The arms were placed at the patient’s side with the hands pointing 
towards the knee. 
6. A rolled towel was placed lengthwise between the shoulders 
along the spine to give the best exposure to the blocking area. 
7. The area was aseptically prepared and draped. 
8. The anesthesiologist stood at the head end of the table. 
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9. The patient was asked to lift the head slightly to bring the 
clavicular head of sternomastoid into prominence. 
10. The index finger was placed lateral to the muscle and the patient 
was asked to relax. The index finger was rolled laterally across 
the belly of the muscle until the inter scalene groove was 
palpated. 
11. The finger was then moved inferiorly down the groove until the 
pulse of subclavian artery was palpated. 
12. A skin wheal was raised at a point about 2 to 2.5 cm above the 
midpoint of clavicle with 1 ml of 2% Lignocaine by a 24 G 
needle. 
13. The palpation of subclavian artery against the palpating finger 
was a guide to supraclavicular block. 
14. A spinal needle was held between the thumb and index finger, 
inserted at the point where we raised local anesthetic wheal. 
15. The needle was directed towards the ipsilateral nipple, 
posterolateral to the subclavian artery. 
16. Within 2cm a pop off was felt or paresthesia was elicited, it 
indicated the needle was inside the sheath and closer to the nerve 
bundle. Then the local anesthetic solution was given in 5ml 
increments with frequent aspiration to prevent intravascular 
injection. 
54 
17. Intercostobrachial nerve and medial cutaneous nerve were 
blocked separately at the axilla anterior to the axillary artery by 
subcutaneous infiltration of local anesthetic to ensure complete 
anesthesia of the upper extremity. 
18. The needle was not advanced beyond 2.5cm to avoid the risk of 
complications. A cough by the patient was a warning that the 
pleura is being irritated by the needle. 
19. After injecting the local anesthetic the block was tested for both 
sensory and motor blockade and was compared with the 
contralateral limb. 
PARAMETERS OBSERVED 
1.  Vital parameters: 
Pulse rate, Blood pressure, and oxygen saturation were monitored 
every minute for the first 5 minutes and every 5 minutes until the end of 
surgery and every 30 minutes thereafter up to regression of motor and 
sensory blockade. For statistical purpose they were documented at 0, 5, 
10, 15, 20, 30, 45 minutes and at the end of surgery.  
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2.  Onset of Analgesia: 
 Onset of analgesia was taken as abolishment of pins prick pain 
over the distribution of ulnar and median and was assessed every minute 
after the performance of the block. 
3.  Onset of motor blockade: 
Onset of motor blockade was assessed every 2 minute after the 
block using four point scales, 
           0- Normal power 
           1- Weakness but able to move arm 
           2- Not able to move arm but the fingers 
           3- Complete motor Blockade 
Attaining a score of 2 was considered as the onset of motor Block. 
4.  Duration of surgery 
5.  Duration of motor Blockade: 
When (3) in the four point scale changes to (2) the motor 
blockade was said to reverse. The duration of motor block is noted from 
the time from scale (3) to scale (3). 
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6.  Duration of sensory blockade:  
The pain was assessed using visual Analogue scale having 10cm 
length numbered from 0 to 10. The pain score was recorded every 30 
minutes after completion of surgery on VAS ranging from 0-10. 
  0  =  complete absence of pain, 
 10  =  worst pain imaginable. 
Duration of sensory blockade was considered as the time interval 
between the complete sensory blockade and pain to pin prick (when 
VAS score >3) .Rescue analgesia was given in the form of IM tramadol 
100mg. 
7.   Sedation score was evaluated every 15 minutes after the injection, 
and was recorded using Brain and Ready Sedation scale given 
below: 
                  0  =  awakened, alert, 
                  1  =  sedated, responding to verbal stimulus, 
                  2  =  sedated, responding to mild physical stimulus, 
         3 = sedated, responding to moderate or strong physical                       
stimulus, 
          4 = not arousable 
57 
8.  Side effects noted are: 
 Hypotension – less than 30% from the baseline 
 Bradycardia – heart rate less than 60 beats/minute 
 nausea  and vomiting  
 sedation score more than 3 was taken as side effect 
 Respiratory depression 
9.  Patients in whom the block was unsuccessful due to total failure 
0f missed dermatomes which needed intravenous supplementation 
or general anaesthesia were excluded from the study. 
STATISTICAL TOOLS 
The information collected regarding all the selected patients were 
recorded in a Master Chart. Results were expressed as mean and 
standard deviation. All statistical analyses were carried out using SPSS 
for Windows version 15.0. The student  t-test was used for comparison 
of quantitative variants. Qualitative variants were compared using the 
chi-square test. A ‘P value’ of less than 0.05 was considered statistically 
significant.  
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OBSERVATIONS AND RESULTS 
Table 1 : Demographic profile: AGE 
Age in 
yrs 
Group-A Group-B Total 
Number Percentage Number Percentage Number Percentage 
20 – 30 15 50.00 11 36.70 26 43.30 
30 – 40 7 23.30 9 30.00 16 26.70 
40 – 50 4 13.30 6 20.00 10 16.70 
50 – 60 4 13.30 4 13.30 8 13.30 
Total 30 100 30 100 30 100 
 
Mean 33.70 35.90 
Sd 11.66 10.92 
t-value 0.75 
Df 58 
p-value 0.45 (Not Significant) 
 
The mean age of group A was 33.70 and group B was 35.90, the p 
value was 0.45, it was not statistically significant. Both groups were 
comparable in terms of age. 
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Table 2 : Demographic profile: SEX 
Sex 
Group –A Group-B Total 
Number % Number % Number % 
Male 25 83.30 24 80.00 49 81.70 
Female 5 16.70 06 20.00 11 18.30 
Total 30 100 30 100 60 100 
Chisqure 0.11   
Df 1   
p-value 0.74 (Not Significant)   
 
 
  The percentage of male patients in group A was 83.3 and in 
group B was 80.0, the percentage of female patients in group A was 
16.7 and in group B was 20.0, p value was 0.74, it was not statistically 
significant. Both groups were comparable in terms of sex.                                                                                                                                                                           
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Table 3 : Demographic profile: Weight 
Weight 
in kgs 
Group-A Group-B Total 
Number Percentage Number Percentage Number Percentage 
50– 55 3 10.00 5 16.70 8 13.30 
55 – 60 4 13.30 6 20.00 10 16.70 
60 – 65 11 36.70 11 36.70 22 36.70 
65 – 70 10 33.30 8 26.70 18 30.00 
70 – 75 2 6.70 0 0 2 3.30 
Total 30 100 30 100 30 100 
 
 Group-A Group-B 
Mean 64.00 61.50 
Sd 5.13 5.43 
p-value 0.07 (Not Significant) 
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 Weight of the patients in the group A had a mean value of 64.00 
kg with standard deviation of 5.13. In Clonidine group, mean value was 
61.50 and standard deviation of 5.43, the p value was 0.07, it was not 
statistically significant .Both groups were comparable in terms of 
weight. 
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Table 4 : Demographic profile: ASA PS 
ASA 
Group-A Group-B 
Number Percentage Number Percentge 
I 27 90.00 28 93.30 
II 03 10.00 02 06.70 
Total 30 100 30 100 
Chisqure 0.22 
Df 1 
p-value 0.64 (Not Significant) 
 
 
In group A 27 patients were ASA I and 3 were ASA II patients. In 
group B 28 patients were in ASA I and 2 were ASA II patients. The data 
was statistically not significant (p>0.05) and both the groups were 
comparable in terms of ASA PS Status. 
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Fig.8 : ASA Status 
I II 
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Table 5 : DURATION OF SURGERY: 
 Group-A Group-B 
Mean 144.33 135.70 
Sd 19.98 19.44 
p-value 0.10 (Not Significant) 
  
 The mean duration of surgery in group A was 144.33, and in 
group B was 135.70. Statistical analysis showed the p value as 0.10. The 
p value was not statistically significant. 
Table 6 : Onset of motor blockade: 
 Group-A Group-B 
Mean 15.30 8.43 
Sd 0.92 1.57 
p-value 0.000 (Significant) 
    
 The mean onset of motor blockade in group A was 15.30 
minutes, in group B was 8.43 minutes. Statistical analysis revealed p 
value as 0.000, it was statistically significant. 
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Table 7 : ONSET OF MOTOR BLOCKADE: 
 Group-A Group-B 
Mean 18.30 13.30 
Sd 1.06 1.66 
p-value 0.000 (Significant) 
  
  The mean onset of sensory blockade in group A was 18.30, and 
in group B was 13.30.statistical analysis revealed p value as 0.000, 
which was statistically significant. 
Table 8 :DURATION OF MOTOR BLOCKADE 
 Group-A Group-B 
Mean 200.83 476.37 
Sd 16.56 57.28 
p-value 0.000 (Significant) 
 
The mean duration of motor blockade in group A was 200.83 
minutes, in group B was 476.37 minutes. Statistical analysis showed the 
p value as  0.000, which was statistically significant.       
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Table 9 : DURATION OF SENSORY BLOCKADE: 
 Group-A Group-B 
Mean 312.77 657.63 
Sd 16.76 39.46 
p-value 0.000 (Significant) 
 
The mean duration of sensory blockade in group A was 312.77 
minutes, in group B was 657.63 minutes. Statistical analysis showed the 
p value as <0.000, which was statistically significant. 
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Table 10 : HEART RATE 
Heart Rate 
Group–A 
Mean ± sd 
Group-B 
Mean ± sd 
t-value 
p-Value 
df=58 
Pre block 82.13 ± 6.79 81.20 ± 5.29 0.59 0.56 
5   Mint 83.53 ± 6.38 82.20 ± 5.37 0.88 0.39 
10   Mint 84.13 ± 6.85 84.40 ± 5.16 0.21 0.83 
15   Mint 84.07 ± 6.79 85.07 ± 4.95 0.67 0.51 
20   Mint 85.00 ± 6.21 86.00 ± 5.23 0.68 0.50 
30   Mint 87.00 ± 4.57 87.87 ± 3.32 0.84 0.40 
45   Mint 88.07 ± 3.66 88.93 ± 2.39 1.09 0.28 
END 88.87 ± 2.86 89.47 ± 1.28 1.05 0.30 
 
The heart rate was measured pre block, 5mins, 10mins, 15mins, 
20mins, 30mins, 45 mins and at the end of the surgery. Statistical 
analysis using student t test showed the p value as 0.560, 0.390, 0.830, 
0.510, 0.50, 0.40, 0.28 and 0.30 respectively, which were statistically 
insignificant. 
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Table 11 : SYSTOLIC BLOOD PRESSURE
 
Systolic Blood 
Pressure 
Group–A 
Mean ± sd 
Group-B 
Mean ± sd 
t-value 
p-Value 
df=58 
Pre block 117.40 ± 7.03 115.47 ± 5.70 1.17 0.25 
5   Mint 116.73 ± 6.31 115.67 ± 5.85 0.68 0.50 
10   Mint 116.23 ± 6.56 117.20 ± 5.67 0.61 0.54 
15   Mint 116.83 ± 6.47 118.00 ± 5.33 0.89 0.38 
20   Mint 117.83 ± 6.70 118.40 ± 5.91 0.35 0.73 
30   Mint 118.47 ± 7.66 120.47 ± 6.00 1.13 0.27 
45   Mint 119.80 ± 9.01 122.80 ± 6.16 1.51 0.14 
END 121.73 ± 8.63 124.47 ± 6.60 1.38 0.17 
 
The systolic blood pressure was measured pre block, 5mins, 
10mins, 15mins, 20mins, 30mins, 45mins and at the end of the surgery. 
Statistical analysis using student t test showed the p value as 0.25, 0.50, 
0.54, 0.38, 0.73, 0.27 .0.14and 0.17 respectively, which were 
statistically insignificant. 
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Fig.10 : Systolic Blood Pressure  
Group–A Group-B 
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Table12 : DIASTOLIC BLOOD PRESSURE 
Diastolic 
Blood 
Pressure 
Group–A 
Mean ± sd 
Group-B 
Mean ± sd 
t-value 
p-Value 
df=58 
Pre block 68.93 ± 4.98 70.07 ± 6.86 0.73 0.47 
5   Mint 66.67 ± 6.11 68.27 ± 7.22 0.93 0.36 
10   Mint 66.40 ± 4.80 65.73 ± 4.42 0.56 0.58 
15   Mint 69.93 ± 5.74 68.80 ± 6.47 0.72 0.48 
20   Mint 72.00 ± 5.87 73.53 ± 5.19 1.07 0.29 
30   Mint 72.20 ± 4.99 73.87 ± 6.08 1.16 0.25 
45   Mint 73.73 ± 5.58 73.67 ± 5.83 0.05 0.96 
END 74.13 ± 6.28 73.20 ± 6.27 0.58 0.57 
 
The diastolic blood pressure was measured pre block, 5mins, 
10mins, 15mins, 20 mins, 30mins, 45mins, and at the end of the surgery. 
The p values were calculated using student t test. The p values were 
statistically insignificant.  
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Fig.11 : Diastolic Blood Pressure Changes  
Group–A Group-B 
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Table13  :MEAN ARTERIAL PRESSURE 
Mean 
arterial 
pressure 
Group–A 
Mean ± sd 
Group-B 
Mean ± sd 
t-value 
p-Value 
df=58 
Pre block 82.88 ± 5.65 83.89 ± 6.12 0.70 0.49
 
5   Mint 83. 47 ± 3.97 83.24 ± 5.22 0.18 0.86
 
10   Mint 83.01 ± 3.30 82.89 ± 3.01 0.15 0.88
 
15   Mint 85 .50 ± 4.40 83. 89 ± 5.29 1.28 0.21
 
20   Mint 87. 28± 4.16 86.78 ± 4.76 0.43 0.67
 
30   Mint 87.62 ± 3.79 89.09 ± 4.67 0.39 0.70
 
45   Mint 89.09 ± 4.67 87.09 ± 4.67 1.63 0.11
 
END 90.00  ± 4.43 90. 29 ± 4.27 0.26 0.80
 
 
The mean arterial pressure was measured pre block, 5mins, 
10mins, 15mins, 20 mins, 30mins, 45mins and at the end of the surgery. 
Statistical analysis using student t test showed p value as 
0.49,0.86,0.88,0.21,0.67,0.70,0.11 and 0.8 respectively. The p values 
were statistically insignificant. 
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Table-14 : SEDATION SCORE 
Sedation score Group-A Group-B 
0 28 0 
1 2 15 
2 0 15 
3 0 0 
4 0 0 
Mean 0 1.50 
Sd 0 0.51 
t-value 13.81 
Df 58 
p-value 0.0001(Significant) 
          
The mean of sedation score in Clonidine group was 1.50, while 
the mean for control group was 0; the p value was 0.0001, which was 
statistically significant. 
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Fig.13 : Sedation Score 
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Table 15 : SIDE EFFECTS 
 Group-A Group-B 
 Number Percentage Number Percentage 
No Side effect 30 100 29 96.67 
Brady Candia 0 0 1 3.33 
Sedation 0 0 0 0 
Respiratory 0 0 0 0 
Nausea 0 0 0 0 
Vomiting 0 0 0 0 
Hypotension 0 0 0 0 
 
 Group-A Group-B 
 Number Percentage Number Percentage 
No Side effect 30 100 29 96.67 
Side effect 0 0 1 3.33 
Chi-square 1.02 
Df 1 
p-value 0.31 (Not Significant) 
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None of the patients in control group developed any side effects 
and one patient in Clonidine group developed bradycardia.  P value was 
0.31, which was statistically not significant.     
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Fig.14 : Side Effects  
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DISCUSSION 
 Brachial plexus block is an easy and relatively safe procedure 
for upper limb surgeries. A combination of Lignocaine and Bupivacaine 
provided better operating conditions but the duration of analgesia is 
rarely maintained for more than 4-6 hours. Various additives have been 
tried in order to prolong the duration of analgesia. In this study, 
Clonidine has been used as an adjuvant to the local anesthetic mixture to 
evaluate its efficacy. 
 A total of 60 patients of ASA grade I or II undergoing upper limb 
surgeries were randomly assigned into two groups, Group A and B. 
Surgery was done under supraclavicular approach to brachial plexus 
block. 
 GROUP A (30):  15 ml 2% Lignocaine with Adrenaline (1in 200000) 
+ 15 ml 0.5% Bupivacaine with 2ml of 0.9% normal 
saline.  
GROUP B (30):    15 ml 2% Lignocaine with Adrenaline (1in 200000) 
+ 15 ml 0.5% Bupivacaine with 1µg /kg of 
Clonidine. 
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 The demographic profile in  all 3 groups were similar and there 
were no significant difference in Age, Sex, ASA physical status and 
Weight. Duration of surgery was around 3 hours in all 3 groups. 
1. Onset of motor blockade and sensory blockade: (Table-6&7) 
In our study, onset of motor blockade and onset of sensory 
blockade occured earlier in Clonidine group.  
Our finding is comparable with the study conducted by Shivinder 
singh et al
18
, they concluded in their study that addition of Clonidine 
resulted in faster onset of sensory and motor blockade. 
In our study motor blockade occured earlier than sensory 
blockade, this finding is comparable with the study conducted by 
Winnie et al
1
, he described the outer motor fibers are blocked earlier 
than the sensory fibers which are situated deeper in the plexus at the 
level of trunk and division.  
2. Duration of motor blockade: (Table - 8) 
The mean duration of motor blockade in group A was 200.83 ± 
16.56 minutes, and in groupB was 476.37 ± 57.28 minutes. The 
difference between the two groups was statistically significant with a p 
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value of 0.000. Addition of Clonidine to the local anesthetic mixture has 
significantly prolonged the duration of motor blockade than the control 
group. 
        These results correlate with the studies conducted by, Eledjam JJ 
et al
3
, in   Clonidine group it was 580.4 ± 38.7 minutes. In another study 
conducted by, E1 saied AH et al
10
 ,the addition of Clonidine 150µg to 
40 ml of Ropivacaine 0.75% prolonged the duration of motor blockade 
significantly. 
3.  Duration of sensory blockade: (Table - 9) 
 The mean duration of post operative analgesia was till the VAS 
score > 3 
Group A=312.77 ± 16.76 minutes 
Group B=657.63 ± 39.46 minutes 
 The difference between the two groups was statistically 
significant with a p value of 0.000. 
 Addition of Clonidine to local anaesthetic solution prolonged 
the post operative analgesia significantly when compared to control 
group.  In the study conducted by Adnan T et al
17
 , the addition of 
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Clonidine to local anesthetic  prolongs the duration of sensory block 
significantly with the P value < 0.001. In the study by Duma A et al
15
, 
findings suggest higher variance in the duration of sensory block within 
the Clonidine. 
 These results correlate favorably with studies conducted by EL 
Saied AH et al
10
, the addition of Clonidine showed duration of sensory 
analgesia from 587 minutes to 828 minutes. ssssIn the study conducted 
by Eledjam JJ
3
 and colleagues the addition of 150 mg Clonidine with 
0.5% Bupivacaine conferred a mean duration of postoperative analgesia 
of 994.2 ± 34.2minutes .In the study by Casati A et al 
12
, the addition of 
Clonidine provided 15.2 hours of  postoperative analgesia.  In the study 
by Erlacher et al
13
, the addition of 150µg of Clonidine to 40ml of 0.5% 
Bupivacaine, the duration of sensory blockade was prolonged to 972±72 
minutes.  
4.  Intraoperative hemodynamic changes: Hemodynamic parameters 
like heart rate, systolic BP, diastolic BP and mean BP was 
comparable in both groups. This was consistent with the 
observation by EL Saied AH
10
 et al, Eledjam JJ
3
 et al  and 
Casati A et al
12
. (Table - 10 -13 & Fig.9 - 12) 
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5.  Sedation score: (Table - 14 & Fig.13) 
 The sedation score in both groups was noted. The sedation score 
in group B was mean 1.50±0.51, in group A was mean 0. In Clonidine 
group since the sedation score was not more than 2, the respiratory 
function was not compromised. So intraoperative sedation is well 
observed in Clonidine group. This finding is consistent with the study 
conducted by Adnan T et al
17
, they concluded that addition of 
Clonidine ,produced sedation without respiratory depression. 
6  Side effects: (Table - 15 & Fig.14) 
 Patients were observed for the side effects like bradycardia, 
hypotension, sedation, dry mouth, dizziness, arrhythmias and local 
anesthetic toxicity .In control group none of the patients developed side 
effects .In Clonidine group one patient developed bradycardia but 
patient was hemodynamically stable hence not treated 
pharmacologically. In the study performed  by  Casati A 
12
 in 2001, no 
significant Clonidine related side effects like sedation or hemodynamic 
instability when added to the local anesthetic was observed. In the study 
by Eledjam JJ
3
 et al, in 1991 none of the patients reported Clonidine 
related side effects .This was consistent with the observation by EL 
Saied AH
10
and colleagues.     
 
84 
SUMMARY 
 This single blinded randomized controlled study was done to 
evaluate the Onset of motor and sensory blockade, Duration of motor 
and sensory blockade, Intraoperative hemodynamic changes, Sedation 
and Side effects of Clonidine used as an adjuvant to the local anesthetic 
mixture in supraclavicular brachial plexus block for upper limb 
orthopedic surgeries. 
  The following observations were made : 
1. The demographic profiles like Age, Sex, weight, ASA status were 
comparable in both groups. 
2. The onset of motor block occured earlier in Clonidine group than 
control group. 
3. The onset of sensory block occured earlier in Clonidine group 
than control group. 
4. The onset of motor block occured earlier than sensory block in 
both groups. 
5. The hemodynamic parameters like heart rate, systolic blood 
pressure, diastolic blood pressure, mean arterial pressure were 
comparable in both the groups. 
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6. The duration of motor block was longer in Clonidine group than 
control group. 
7. The duration of sensory block was longer in Clonidine group than 
control group. 
8. In Clonidine group, intraoperative sedation was well observed 
without compromising respiratory functions. 
9. There was no significant side effects between the two groups. 
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CONCLUSION 
The addition of Clonidine 1µg/kg to local anesthetic mixture in 
supraclavicular approach to brachial plexus fastens the onset of action of 
motor and sensory blockade, and prolongs the duration of motor 
blockade and analgesia significantly without any significant side effects. 
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PATIENT CONSENT FORM 
Study title        : “PROSPECTIVE RANDOMISED CONTROL STUDY ON THE 
EFFECTIVENESS OF CLONIDINE 1MCG/KG AS AN ADJUVANT 
TO LOCAL ANAESTHETIC MIXTURE OF 2% LIGNOCAINE  
WITH ADRENALINE AND 0.5% BUPIVACAINE IN 
SUPRACLAVICULAR BRACHIAL PLEXUS BLOCK FOR 
PROVIDING POST OPERATIVE ANALGESIA IN UPPER LIMB 
ORTHOPAEDIC SURGERIES ’’ . 
Study centre:         Institute  of Anaesthesiology  and  Critical Care, 
Rajiv  Gandhi Govt Hospital, Chennai. 
 
Participant name :                                 Age:                         Sex:                      
I.P.No: 
I confirm that I have understood the purpose of procedure for the above 
study .i have the opportunity to ask the question and all my questions and doubts 
have been answered to my satisfaction. 
            I have been explained about the pitfall in the procedure.  I have been 
explained about the safety, advantage and disadvantage of the technique. 
            I understand that my participation in the study is voluntary and that i am free 
to withdraw at anytime without giving any reason. 
            I understand that investigator ,regulatory authorities and the ethics committee 
will not need my permission to look at my health records both in respect to current 
study and any further research that may be conducted in relation to it, even if i 
withdraw from the study . I understand that my identity will not be revealed in any 
information released to third parties or published , unless as required under the law . 
I agree not to restrict the use of any data or results that arise from the study . 
 
Time:          
 
Date:                              Signature / thumb impression of patient  
 
Place:                                                              Patient name: 
 
Signature of the investigator: 
 
Name of the investigator: 
 
  
PROFORMA 
PROSPECTIVE, RANDOMISED, SINGLE BLINDED, CONTROLLED 
STUDY ON THE EFFECTIVENESS OF CLONIDINE AS AN ADJUVANT 
TO LOCAL ANESTHETIC MIXTURE IN PROVIDING POSTOPERATIVE 
ANALGESIA FOR SUPRACLAVICULAR BRACHIAL PLEXUS BLOCK 
NAME :                       AGE :   SEX :    I.P.No :  
DIAGNOSIS :    SURGERY PLANNED:  
Group A/B                       Dose of Clonidine: 
 
PREOPERATIVE ASSESSMENT:  
HISTORY:  
CO-MORBID ILLNESS & TREATMENT DETAILS:  
EFFORT TOLERANCE- _______ METS 
H/O PREVIOUS SURGERY : 
H/O DRUG ALLERGY : 
 
GENERAL EXAMINATION:  
HEIGHT:                                 WEIGHT:                       
ANAEMIA-  JAUNDICE-  PEDAL EDEMA -         AIRWAY-  
PULSE-  BP-   CVS-           RS- 
 
INVESTIGATIONS: 
Hb :  BT:  CT:  BLOOD GROUPING & TYPING: 
BLOOD SUGAR:  UREA: CREATININE: 
ECG:    CXR: 
  
SUPRACLAVICULAR BLOCK : 
Perivascular technique  
 
PARAMETERS TO BE OBSERVED: 
Time of onset of sensory blockade             
Time of onset of motor blockade           
Intraoperative hemodynamic changes            
Duration of sensory blockade  
Duration of motor blockade 
Sedation score 
 
INTRA OP VITAL PARAMETERS: 
TIME PR SBP DBP SpO2 RR Side Effects 
Base line       
5 min       
10 min       
15 min       
20 min       
25 min       
30 min       
35 min       
40 min       
45 min       
50 min       
55 min       
60 min       
65 min       
70 min       
75 min       
80 min       
85 min       
90 min       
 
SIDE EFFECTS : 
Side effects  
Nausea / vomiting  
Bradycardia  
Hypotension  
Sedation  
 
INTRA OP EVENTS:   
IV FLUIDS : 
CONVERSION TO GA : 
PAIN SCORE : (VERBAL RATING SCALE) 
ENDING TIME : Onset of pain and motor regression in the postoperative 
period 
  
VAS SCALE 
 
 
Visual Analog Scale (VAS) 
 
 
 
  Very           Hurts just         Hurts a         Hurts even      Hurts a          Hurts as 
Happy,        a little bit.        little more.           more.       Whole lot.    Much as you 
no hurt.                                                                                            can imagine 
 
 
0              1         2         3         4        5         6        7        8        9        10        
No pain                                                                                    severe pain 
 
 
 
 
MASTER CHART
SLNO Name Group Age sex ASA Weight MB SB DOS DOMB DOSB HRBL HR5 HR10 HR15 HR20 HR30 HR45 HREND
1 UMAPATHY B 41 m I 56 10 15 140 455 620 76 88 90 80 90 90 90 90
2 SAMPATH B 22 m I 65 12 16 132 423 585 82 82 86 90 90 90 90 90
3 PARTHIBAN B 20 m I 60 10 15 100 465 640 74 76 74 90 76 78 78 84
4 RANGASAMY B 42 m I 58 9 14 120 476 560 84 80 80 84 80 82 88 88
5 RAVI B 32 m I 62 5 15 146 375 590 78 78 80 90 90 90 90 90
6 BALASUNDAR B 30 m I 70 6 12 155 410 675 78 78 76 88 72 90 90 90
7 CHANDRA B 34 f I 55 9 14 160 450 668 86 88 88 84 90 90 90 90
8 ANTONY B 45 m I 63 10 15 142 486 630 84 80 80 86 86 88 88 90
9 ANNALAKSHMI B 25 f I 56 8 12 115 462 642 78 74 78 88 78 86 90 90
10 PALANI B 40 m I 68 7 12 120 466 665 88 88 90 90 90 90 90 90
11 MUTHUKUMAR B 22 m I 63 9 14 148 628 710 82 80 86 86 86 86 86 88
12 KUMAR B 27 m I 66 10 15 150 480 590 76 84 84 82 86 88 88 88
13 YEGAMBARAM B 48 m II 68 8 13 136 510 680 84 84 88 90 80 88 90 90
14 FRAKLYN B 36 m I 62 10 14 132 490 646 88 88 90 80 90 90 90 90
15 JESUDASS B 31 m I 61 7 12 148 426 650 82 84 88 82 90 90 90 90
16 RASIAMMAL B 29 f I 55 9 14 170 440 668 88 80 86 86 86 86 88 88
17 YUVRAJ B 24 m I 60 7 12 126 455 690 88 88 88 90 90 90 90 90
18 PURUSHOTHANAM B 52 m II 64 9 15 135 610 712 84 88 88 84 88 90 90 90
19 ILLAVARASI B 27 f I 50 10 14 156 460 650 74 74 78 88 88 88 90 90
20 GIRISH B 22 m I 56 8 14 120 450 680 86 86 90 90 90 90 90 90
21 HABEEB B 28 m I 61 9 15 138 520 690 74 78 86 80 86 88 90 90
22 THIAGU B 36 m I 68 7 12 145 490 650 88 86 84 84 84 86 88 90
23 MALA B 32 f I 54 6 10 150 530 680 76 76 78 88 90 90 90 90
24 PONNI B 37 f I 52 8 12 162 470 635 88 88 88 88 88 90 90 90
25 VENDAN B 46 m I 68 8 13 140 612 725 88 88 88 82 90 90 90 90
26 ARULPRAKASAM B 48 m I 66 10 14 105 460 660 74 74 74 74 74 78 88 90
27 MAYANDI B 54 m I 62 9 14 90 440 683 74 72 80 82 86 86 86 88
28 TILAK B 55 m I 70 6 9 156 460 700 76 88 88 86 88 88 90 90
29 THENDRAL B 58 m I 64 8 11 120 472 675 80 80 88 70 88 90 90 90
30 XAVIER B 34 m I 62 9 12 114 420 680 78 88 90 90 90 90 90 90
MASTER CHART
SLNO Name Group
1 UMAPATHY B
2 SAMPATH B
3 PARTHIBAN B
4 RANGASAMY B
5 RAVI B
6 BALASUNDAR B
7 CHANDRA B
8 ANTONY B
9 ANNALAKSHMI B
10 PALANI B
11 MUTHUKUMAR B
12 KUMAR B
13 YEGAMBARAM B
14 FRAKLYN B
15 JESUDASS B
16 RASIAMMAL B
17 YUVRAJ B
18 PURUSHOTHANAM B
19 ILLAVARASI B
20 GIRISH B
21 HABEEB B
22 THIAGU B
23 MALA B
24 PONNI B
25 VENDAN B
26 ARULPRAKASAM B
27 MAYANDI B
28 TILAK B
29 THENDRAL B
30 XAVIER B
SBPBL SBP5 SBP10 SBP15 SBP20 SBP30 SBP45 SBPEND DBPBL DBP0 DBP10 DBP15 DBP20M DBP30M DBP45 DBPEND MAPBL
108 110 110 118 108 108 108 118 60 62 60 70 86 82 80 80 78.00
120 120 120 120 120 120 120 120 72 66 62 70 70 70 74 74 82.00
110 116 120 120 120 120 122 122 76 68 62 70 82 74 68 70 79.33
118 118 120 120 120 128 128 130 76 70 66 78 72 78 70 70 84.00
112 112 112 116 120 122 124 126 72 70 68 68 74 84 78 78 83.33
110 104 110 110 110 116 120 122 70 80 60 60 76 72 74 74 93.33
118 118 120 120 122 128 130 130 60 60 64 64 70 70 74 74 79.33
116 116 118 120 122 124 126 128 80 76 70 72 72 70 72 72 88.00
118 120 120 120 120 120 120 120 90 90 70 72 76 76 70 70 99.33
110 110 116 118 118 120 124 126 70 70 70 70 70 70 74 74 83.33
106 108 110 110 110 116 118 124 70 70 66 66 74 72 70 70 82.00
118 118 120 120 120 126 128 130 70 74 66 68 70 72 76 80 90.00
114 114 114 114 114 118 128 130 68 60 60 70 80 70 70 70 75.33
130 110 110 110 110 110 110 114 70 66 66 66 74 80 80 80 86.00
120 120 120 120 122 126 128 128 72 70 76 70 70 64 64 64 86.00
110 110 110 112 112 116 116 118 74 74 70 70 70 60 60 60 86.00
110 110 120 120 120 120 120 130 72 70 70 70 72 80 80 80 89.33
116 118 120 122 124 126 128 130 70 70 70 70 70 74 76 76 90.00
110 118 118 118 118 118 120 124 66 60 66 70 72 74 72 72 74.67
120 120 122 122 122 122 124 128 64 66 60 74 74 74 76 76 84.67
120 124 124 124 124 126 126 128 64 60 60 70 70 80 80 80 78.67
120 122 122 122 122 122 126 106 66 66 62 76 80 80 80 80 84.00
110 110 110 110 110 110 116 110 66 60 70 72 80 80 80 80 74.67
114 114 114 118 120 124 130 130 60 60 66 74 60 60 70 70 78.00
110 108 108 108 108 108 110 116 70 70 72 40 70 70 70 70 83.33
120 120 126 126 126 126 126 130 80 80 64 70 70 72 72 72 96.67
126 130 130 130 130 130 130 130 64 60 60 64 70 80 80 60 80.67
120 120 120 120 126 126 126 130 70 70 68 70 80 80 80 80 86.67
120 122 122 122 122 122 122 126 80 70 60 70 72 78 80 80 83.33
110 110 110 110 112 116 130 130 60 60 68 70 80 70 60 60 76.67
MASTER CHART
SLNO Name Group
1 UMAPATHY B
2 SAMPATH B
3 PARTHIBAN B
4 RANGASAMY B
5 RAVI B
6 BALASUNDAR B
7 CHANDRA B
8 ANTONY B
9 ANNALAKSHMI B
10 PALANI B
11 MUTHUKUMAR B
12 KUMAR B
13 YEGAMBARAM B
14 FRAKLYN B
15 JESUDASS B
16 RASIAMMAL B
17 YUVRAJ B
18 PURUSHOTHANAM B
19 ILLAVARASI B
20 GIRISH B
21 HABEEB B
22 THIAGU B
23 MALA B
24 PONNI B
25 VENDAN B
26 ARULPRAKASAM B
27 MAYANDI B
28 TILAK B
29 THENDRAL B
30 XAVIER B
MAP5 MAP10 MAP15 MAP20 MAP30 MAP45 MAPEND BRADYCARDIA SEDATION RESPIRATORY NAUSEA VOMITING HYPOTENSION SEDATION 
SCORE
75.33 76.67 86.00 93.33 90.67 89.33 92.67 no no no no no no 1
80.67 81.33 86.67 80.00 80.00 83.33 89.33 no no no no no no 1
84.00 81.33 83.33 94.67 89.33 86.00 87.33 no no no no no no 1
86.00 84.00 92.00 88.00 94.67 89.33 90.00 no no no no no no 2
82.67 82.67 86.67 88.67 93.33 88.67 94.00 yes no no no no no 2
88.00 76.67 76.67 87.33 85.33 86.00 90.00 no no no no no no 2
73.33 82.67 78.67 83.33 82.67 83.33 92.67 no no no no no no 1
85.33 86.00 84.67 85.33 84.00 87.33 90.67 no no no no no no 2
100.00 86.67 88.00 90.67 90.67 86.67 86.67 no no no no no no 1
80.00 85.33 83.33 80.00 80.00 84.00 91.33 no no no no no no 1
82.67 80.67 80.67 86.00 85.33 86.00 88.00 no no no no no no 2
88.67 84.00 84.67 86.67 90.00 93.33 96.67 no no no no no no 2
78.00 78.00 81.33 91.33 93.33 84.00 90.00 no no no no no no 1
80.67 80.67 78.67 84.00 86.67 86.67 91.33 no no no no no no 1
86.00 90.67 83.33 83.33 78.67 78.67 85.33 no no no no no no 2
86.00 83.33 84.00 84.00 75.33 76.67 79.33 no no no no no no 2
83.33 86.67 83.33 84.67 90.00 90.00 96.67 no no no no no no 1
86.00 86.67 87.33 83.33 82.67 94.00 94.00 no no no no no no 2
76.00 83.33 82.67 84.00 84.67 85.33 89.33 no no no no no no 2
84.00 80.67 90.00 90.00 90.00 90.00 93.33 no no no no no no 2
81.33 81.33 86.67 83.33 88.67 88.67 96.00 no no no no no no 1
84.67 82.00 91.33 94.00 94.00 90.00 88.67 no no no no no no 1
76.67 83.33 84.67 90.00 90.00 87.33 90.00 no no no no no no 1
78.00 82.00 84.00 74.67 74.67 83.33 90.00 no no no no no no 1
82.67 84.00 62.67 82.67 82.67 80.67 85.33 no no no no no no 2
93.33 84.67 85.33 85.33 86.67 88.00 91.33 no no no no no no 2
83.33 83.33 86.00 90.00 96.67 96.67 83.33 no no no no no no 2
86.67 85.33 83.33 95.33 95.33 95.33 96.67 no no no no no no 2
87.33 80.67 87.33 88.67 92.67 94.00 95.33 no no no no no no 1
76.67 82.00 83.33 90.67 85.33 80.00 83.33 no no no no no no 1
